

TABLE 182: NAIVE SVR GENOTYPE 4 ALL (INCLUDING EMERGING TREATMENTS) WITH PEARL-I STUDY ADDED: ODDS RATIOS, RELATIVE RISKS, AND RISK DIFFERENCE FOR ALL TREATMENT COMPARISONS — RANDOM EFFECTS MODEL

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SOF12 + RBV12	PR 48	0.99 (0.05 to 1.81)	-0.63 (-49.08 to 41.91)
SOF24 + RBV24		1.63 (1.19 to 1.84)	32.32 (9.57 to 43.30)
SOF12 PR12		1.86 (1.57 to 1.94)	44.23 (29.44 to 48.04)
GRZ12 + ELB12		1.82 (1.41 to 1.93)	42.18 (21.06 to 47.78)
DCV12 + ASU12 + BEC12 (75 mg b.i.d.)		1.82 (1.29 to 1.94)	42.41 (15.18 to 48.18)
DCV12 + ASU12 + BEC12 (150 mg b.i.d.)		1.80 (1.20 to 1.93)	41.56 (10.28 to 47.98)
PAR/RIT12 + OMB12 + RBV12		1.88 (1.67 to 1.94)	45.50 (34.55 to 48.19)
SOF24 + RBV24	SOF12 + RBV12	1.61 (0.91 to 30.18)	30.98 (-7.97 to 79.42)
SOF12 PR12		1.85 (1.00 to 36.30)	43.58 (-0.13 to 93.91)
GRZ12 + ELB12		1.81 (0.94 to 33.51)	41.30 (-5.12 to 90.31)
DCV12 + ASU12 + BEC12 (75 mg b.i.d.)		1.79 (0.90 to 35.42)	40.55 (-8.51 to 92.88)
DCV12 + ASU12 + BEC12 (150 mg b.i.d.)		1.78 (0.87 to 33.49)	39.86 (-11.37 to 91.18)
PAR/RIT12 + OMB12 + RBV12		1.89 (1.02 to 36.00)	45.33 (2.01 to 94.13)
SOF12 PR12	SOF24 + RBV24	1.13 (0.94 to 1.54)	11.15 (-5.06 to 33.90)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
GRZ12 + ELB12		1.11 (0.85 to 1.52)	9.14 (-13.20 to 32.38)
DCV12 + ASU12 + BEC12 (75 mg b.i.d.)		1.11 (0.79 to 1.52)	9.26 (-18.23 to 32.88)
DCV12 + ASU12 + BEC12 (150 mg b.i.d.)		1.10 (0.74 to 1.51)	8.27 (-22.94 to 32.02)
PAR/RIT12 + OMB12 + RBV12		1.15 (0.98 to 1.57)	12.51 (-1.53 to 35.34)
GRZ12 + ELB12	SOF12 PR12	0.98 (0.77 to 1.16)	-1.81 (-22.38 to 13.16)
DCV12 + ASU12 + BEC12 (75 mg b.i.d.)		0.98 (0.70 to 1.16)	-1.53 (-28.64 to 13.45)
DCV12 + ASU12 + BEC12 (150 mg b.i.d.)		0.98 (0.65 to 1.15)	-2.30 (-32.90 to 12.68)
PAR/RIT12 + OMB12 + RBV12		1.01 (0.90 to 1.19)	1.09 (-9.81 to 15.70)
DCV12 + ASU12 + BEC12 (75 mg b.i.d.)	GRZ12 + ELB12	1.00 (0.72 to 1.28)	0.25 (-26.09 to 20.99)
DCV12 + ASU12 + BEC12 (150 mg b.i.d.)		0.99 (0.68 to 1.27)	-0.61 (-29.98 to 20.32)
PAR/RIT12 + OMB12 + RBV12		1.03 (0.91 to 1.33)	3.01 (-8.42 to 23.88)
DCV12 + ASU12 + BEC12 (150 mg b.i.d.)	DCV12 + ASU12 + BEC12 (75 mg b.i.d.)	1.00 (0.68 to 1.37)	-0.46 (-30.12 to 25.47)
PAR/RIT12 + OMB12 + RBV12		1.03 (0.91 to 1.43)	2.62 (-8.82 to 29.15)
PAR/RIT12 + OMB12 + RBV12	DCV12 + ASU12 + BEC12 (150 mg b.i.d.)	1.04 (0.91 to 1.55)	3.36 (-8.70 to 34.44)
Random effect model	Residual deviance	12.15 vs. 13 data points	
	Deviance information criteria	83.193	
Fixed effect model	Residual deviance	11.96 vs. 13 data points	
	Deviance information criteria	82.865	

ASU = asunaprevir; BEC = beclabuvir; b.i.d. = twice daily; Crl = credible interval; DAS = dasabuvir; DCV = daclatasvir; ELB = elbasvir; GRZ = grazoprevir; LDV = ledipasvir; OMB = ombitasvir; PAR = paritaprevir; PR = pegylated interferon plus ribavirin; RBV = ribavirin; RD = risk difference; RGT = response-guided therapy; RIT = ritonavir; RR = relative risk; SIM = simeprevir; SOF = sofosbuvir; SVR = sustained virologic response; T = telaprevir; vs. = versus.

Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.